Results 161 to 170 of about 81,917 (261)

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

tRNA‐Derived Small RNAs in Digestive Cancers: From Translational Regulation to Immune and Extracellular Communication

Cancer Science, EarlyView.
tRNA‐derived small RNAs (tsRNAs) function in digestive cancers across three scales: intracellular translational and metabolic control, extracellular vesicle–mediated immune remodeling, and systemic and host–microbe communication. This review organizes these mechanisms by evidence strength, from well‐established intracellular roles to emerging ...
Wang Xitan, Li Han
wiley   +1 more source

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy. [PDF]

JCI Insight
Ogino A, Vajdi A, Mu XJ, Mahadevan NR, Ngo K, Booker MA, Cejas P, Okoro JJ, Xu M, Springer BF, Eschle BK, Messier CM, Wang S, Syamala S, Tamen RM, Adeni AE, Chambers ES, Canadas I, Thai T, Christensen CL, Xu C, Lizotte PH, Oxnard GR, Watanabe H, Long HW, Gokhale PC, Paweletz CP, Sholl LM, Oser MG, Barbie DA, Tolstorukov MY, Jänne PA.   +31 more
europepmc   +1 more source

m6A‐Mediated Stabilization of MRPS23 Drives NSCLC Progression Via HSPA8 and ERK Signaling Modulation

Cancer Science, EarlyView.
MRPS23 mRNA is m6A‐methylated by WTAP and stabilized by IGF2BP3, leading to increased MRPS23 protein. MRPS23 physically interacts with HSPA8, and this interaction is functionally associated with activation of the RAS–RAF–MEK–ERK pathway, ultimately promoting NSCLC cell proliferation and tumor progression.
Sihong Le, Yitao Le, Xianshen Sha, Feng Qiu, Ling Zhang   +4 more
wiley   +1 more source

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma. [PDF]

JCI Insight
Pan S, Mirchia K, Payne E, Liu SJ, Al-Adli N, Peeran Z, Shukla P, Young JS, Gupta R, Wu J, Pak J, Ozawa T, Na B, Reddy AT, Braunstein SE, Phillips JJ, Chang S, Solomon DA, Perry A, Raleigh DR, Berger MS, Abate AR, Vasudevan HN.   +22 more
europepmc   +1 more source

Genotype‐Informed Whole‐Animal Kinome Screening Reveals Shared Kinase Vulnerabilities Across Driver Contexts in PDAC

Cancer Science, EarlyView.
Overview of experimental workflow and key findings. Clinically prevalent 2‐hit and 3‐hit PDAC genotypes were first modeled in Drosophila to enable kinome‐wide genetic screening. Candidate therapeutic targets were prioritized using human tumor expression data and pathway enrichment analyses.
Han Hai, Takako Ooshio, Hui Jiang, Taku Kimura, Yusuke Satoh, Soichiro Hata, Taiga Hirata, Jiayi Liu, Tongwei Liu, Ryodai Yamamura, Masahiro Sonoshita   +10 more
wiley   +1 more source

Cutaneous Rosai-Dorfman disease with near-complete response to the MEK inhibitor cobimetinib. [PDF]

JAAD Case Rep
Rallapalle V, Kole L, Pavlidakey P, Bhambhvani P, Harada S, Ravindran A, Goyal G.   +6 more
europepmc   +1 more source

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

Cancer Science, EarlyView.
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi, John V. Heymach, Yoshitsugu Horio, Fumihiro Tanaka, Hiroshi Tanaka, Shoichi Kuyama, Morihito Okada, Shinichi Toyooka, Yasutaka Watanabe, Martin Reck, David Harpole, Janis M. Taube, Yuka Olivo, Huiling Xiong, Tamer M. Fouad, Allen Chen, Hiroaki Akamatsu   +16 more
wiley   +1 more source

Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma. [PDF]

Pigment Cell Melanoma Res
Tellenbach FL, Seiler L, Johnson M, Rehrauer H, Schukla P, Martinez-Gomez J, Stoffel CI, Kamal A, Dummer R, Levesque MP, Eichhoff OM.   +10 more
europepmc   +1 more source

Disseminated Xanthogranuloma Harboring a GAB2::BRAF Fusion and MITF Pathogenic Variant Successfully Treated With Cobimetinib: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Several activating mutations and gene fusions involving the mitogen‐activated protein kinase (MAPK) pathway have appeared in the literature regarding histiocytic neoplasms. We identified a GAB2::BRAF fusion in a cutaneous lesion of a 36‐year‐old male who developed central diabetes insipidus and reddish‐pink grouped papules on the bilateral ...
Pauline C. Xu, Allison M. Cushman‐Vokoun, Christopher R. D’Angelo, Dinesh Pradhan   +3 more
wiley   +1 more source